Cargando…

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study

BACKGROUND: Major depressive disorder (MDD) is associated with significant impairments in health-related quality of life (HRQoL) and everyday functioning. This cohort study investigated the long-term development of HRQoL in patients with MDD and its association with patient characteristics, includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Saragoussi, Delphine, Christensen, Michael Cronquist, Hammer-Helmich, Lene, Rive, Benoît, Touya, Maëlys, Haro, Josep Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973321/
https://www.ncbi.nlm.nih.gov/pubmed/29872301
http://dx.doi.org/10.2147/NDT.S159276
_version_ 1783326595034906624
author Saragoussi, Delphine
Christensen, Michael Cronquist
Hammer-Helmich, Lene
Rive, Benoît
Touya, Maëlys
Haro, Josep Maria
author_facet Saragoussi, Delphine
Christensen, Michael Cronquist
Hammer-Helmich, Lene
Rive, Benoît
Touya, Maëlys
Haro, Josep Maria
author_sort Saragoussi, Delphine
collection PubMed
description BACKGROUND: Major depressive disorder (MDD) is associated with significant impairments in health-related quality of life (HRQoL) and everyday functioning. This cohort study investigated the long-term development of HRQoL in patients with MDD and its association with patient characteristics, including depressive symptom severity and cognitive symptoms. METHODS: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study was a longitudinal cohort study conducted in 1,159 outpatients aged 18–65 years with MDD in France, Germany, Spain, Sweden, and the UK. The patients were either initiating antidepressant monotherapy or undergoing their first switch of antidepressant. HRQoL was assessed using the Medical Outcomes Study Short-Form 12-item Health Survey (SF-12) up to month 12 and the EuroQol Five Dimensions questionnaire up to month 24 (UK only). Depressive symptom severity was assessed up to month 24 by the patient-reported Patient Health Questionnaire and cognitive symptoms by the Perceived Deficit Questionnaire. Multivariate analyses were performed to identify patient characteristics associated with HRQoL. RESULTS: Mental HRQoL was severely impaired at baseline versus normative data (mean [SD] SF-12 mental component summary [MCS], 26.5 [9.2]); mean (SD) physical component summary (PCS) total score was 45.2 (12.1). SF-12 MCS improved over 12 months of follow-up (38.7 [11.6] at month 12), while SF-12 PCS remained stable (45.3 [11.1]). At each assessment time point, there was a clear pattern of lower SF-12 MCS and PCS total score in patients experiencing greater cognitive problems. The mean EuroQol Five Dimensions questionnaire utility index score generally decreased (i.e., worsened) with increasing severity of cognitive and depressive symptoms at all time points up to 24 months. Multivariate analyses identified both depression severity and cognitive symptoms as strongly and significantly associated with poor HRQoL. CONCLUSION: These findings highlight the importance of recognizing and managing residual symptoms in patients with MDD, including the cognitive symptoms, to restore long-term psychosocial functioning.
format Online
Article
Text
id pubmed-5973321
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59733212018-06-05 Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study Saragoussi, Delphine Christensen, Michael Cronquist Hammer-Helmich, Lene Rive, Benoît Touya, Maëlys Haro, Josep Maria Neuropsychiatr Dis Treat Original Research BACKGROUND: Major depressive disorder (MDD) is associated with significant impairments in health-related quality of life (HRQoL) and everyday functioning. This cohort study investigated the long-term development of HRQoL in patients with MDD and its association with patient characteristics, including depressive symptom severity and cognitive symptoms. METHODS: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study was a longitudinal cohort study conducted in 1,159 outpatients aged 18–65 years with MDD in France, Germany, Spain, Sweden, and the UK. The patients were either initiating antidepressant monotherapy or undergoing their first switch of antidepressant. HRQoL was assessed using the Medical Outcomes Study Short-Form 12-item Health Survey (SF-12) up to month 12 and the EuroQol Five Dimensions questionnaire up to month 24 (UK only). Depressive symptom severity was assessed up to month 24 by the patient-reported Patient Health Questionnaire and cognitive symptoms by the Perceived Deficit Questionnaire. Multivariate analyses were performed to identify patient characteristics associated with HRQoL. RESULTS: Mental HRQoL was severely impaired at baseline versus normative data (mean [SD] SF-12 mental component summary [MCS], 26.5 [9.2]); mean (SD) physical component summary (PCS) total score was 45.2 (12.1). SF-12 MCS improved over 12 months of follow-up (38.7 [11.6] at month 12), while SF-12 PCS remained stable (45.3 [11.1]). At each assessment time point, there was a clear pattern of lower SF-12 MCS and PCS total score in patients experiencing greater cognitive problems. The mean EuroQol Five Dimensions questionnaire utility index score generally decreased (i.e., worsened) with increasing severity of cognitive and depressive symptoms at all time points up to 24 months. Multivariate analyses identified both depression severity and cognitive symptoms as strongly and significantly associated with poor HRQoL. CONCLUSION: These findings highlight the importance of recognizing and managing residual symptoms in patients with MDD, including the cognitive symptoms, to restore long-term psychosocial functioning. Dove Medical Press 2018-05-22 /pmc/articles/PMC5973321/ /pubmed/29872301 http://dx.doi.org/10.2147/NDT.S159276 Text en © Saragoussi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Saragoussi, Delphine
Christensen, Michael Cronquist
Hammer-Helmich, Lene
Rive, Benoît
Touya, Maëlys
Haro, Josep Maria
Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title_full Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title_fullStr Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title_full_unstemmed Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title_short Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
title_sort long-term follow-up on health-related quality of life in major depressive disorder: a 2-year european cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973321/
https://www.ncbi.nlm.nih.gov/pubmed/29872301
http://dx.doi.org/10.2147/NDT.S159276
work_keys_str_mv AT saragoussidelphine longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy
AT christensenmichaelcronquist longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy
AT hammerhelmichlene longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy
AT rivebenoit longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy
AT touyamaelys longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy
AT harojosepmaria longtermfollowuponhealthrelatedqualityoflifeinmajordepressivedisordera2yeareuropeancohortstudy